ANEBULO PHARMACEUTICALS, INC. — Net Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/229f2c25-af74-4172-b61b-18e1557d9a66/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-8.5M | 2024-07-01 – 2025-06-30 | evidence 0001493152-25-016015 |
| FY 2024 | $-8.2M | 2023-07-01 – 2024-06-30 | evidence 0001493152-24-038127 |
| FY 2023 | $-11.7M | 2022-07-01 – 2023-06-30 | evidence 0001493152-23-033452 |
| FY 2022 | $-6.8M | 2021-07-01 – 2022-06-30 | evidence 0001493152-22-025448 |
| FY 2021 | $-30.3M | 2020-07-01 – 2021-06-30 | evidence 0001493152-21-023373 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ANEBULO PHARMACEUTICALS, INC. — all facts · Operating Income